Why the study?
Stent thrombosis is a devastating complication of PCI, but definitive management and preventive methods remain negligible.
Case Report (n=2)
No
Switching from clopidogrel to a more potent antiplatelet agent like ticagrelor may be considered in patients experiencing stent thrombosis despite good compliance.
Answers are grounded in this paper and cite their sources.
Pericarditis may complicate subacute stent thrombosis; case reports leave open distinct mechanisms and management implications.
Stent thrombosis is a devastating complication of percutaneous coronary intervention (PCI) associated with significant morbidity and mortality. Progressive technical advancements from balloon angioplasty to bare-metal stent and drug-eluting stent placement have reduced the incidence of stent thrombosis. Definitive management and preventive methods are still negligible. Here, we describe two cases of definite subacute stent thrombosis of the right coronary complicated by pericarditis and very late left anterior descending stent thrombosis after the intervention in the right coronary artery. In both cases, antiplatelet treatment with clopidogrel showed excellent compliance. Therefore, after successful PCI, we switched both cases from clopidogrel to potentially more potent antiplatelet treatment, such as ticagrelor, to reduce the occurrence of stent thrombosis in the future.
No takes yet. Share an insight, caveat, or question.
Fadah et al. (2021) conducted a case report in Stent thrombosis post-PCI (n=2). Repeat PCI with aspiration thrombectomy and transition to ticagrelor was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: